

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 12, 2026

Enovis Corporation

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34045
(Commission
File Number)

54-1887631
(I.R.S. Employer
Identification No.)

**2711 Centerville Road, Suite 400
Wilmington, DE 19808**
(Address of principal executive offices) (Zip Code)

(302) 252-9160
(Registrant's telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	ENOV	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

As previously announced, Enovis Corporation's management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 4:30 p.m. PST (7:30 p.m. EST).

A link to the live webcast presentation, as well as a copy of the accompanying presentation materials, will be available at www.enovis.com. A link to a replay of the presentation will also be available on the Enovis website later in the day.

A copy of the presentation materials is also attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished to the Securities and Exchange Commission ("SEC") and shall not be deemed to be incorporated by reference into any of Enovis' filings with the SEC under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) *Exhibits:*

Exhibit Number **Description**

99.1 [Presentation dated January 12, 2026](#)

104 Cover Page Interactive Data File - The cover page from this Current Report on Form 8-K is formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2026

ENOVIS CORPORATION

By: /s/ Bradley J. Tandy

Name: Bradley J. Tandy

Title: Senior Vice President and Chief Legal Officer



2026 JP Morgan Healthcare Conference

Damien McDonald
Chief Executive Officer

Ben Berry
Chief Financial Officer

Kyle Rose
Vice President, Investor Relations

enovisTM
*Creating Better Together*TM



Forward-looking Statements



This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis' current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis' results to differ materially from current expectations include, but are not limited to, risks and uncertainties related to Enovis' business, including with respect to the acquisition of LimaCorporate S.p.A; the impact of public health emergencies and global pandemics; disruptions in the global economy caused by escalating geopolitical tensions including in connection with Russia's invasion of Ukraine; macroeconomic conditions, including the impact of inflationary pressures; changes in government trade policies, including the implementation of tariffs; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; other impacts on Enovis' business and ability to execute business continuity plans; and the other factors detailed in Enovis' reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors," as well as the other risks discussed in Enovis' filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

enovis

© 2026 Enovis Corporation

Non-GAAP Financial Information



Enovis has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations, adjusted net income per diluted share, adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), adjusted EBITDA margin, organic sales growth (also referred to herein as organic growth), free cash flow and free cash flow conversion. Adjusted net income and adjusted net income per diluted share refer to net income and net income per share, respectively, excluding net income attributable to noncontrolling interest from continuing operations, net of taxes; the effect of loss from discontinued operations, net of taxes; restructuring charges; Medical Device Regulation ("MDR") fees and other costs; strategic transaction costs; stock-based compensation; acquisition related intangible asset amortization; strategic purchase of economic interest on future royalty payments; property plant and equipment step-up depreciation, and fair value charges on acquired inventory; goodwill impairment charges; other (income) expense, net; and including the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Enovis also presents adjusted net income margin, which is subject to the same adjustments as adjusted net income. Adjusted EBITDA represents adjusted net income or loss from continuing operations excluding interest, taxes, and depreciation and amortization. Enovis presents adjusted EBITDA margin, which is subject to the same adjustments as adjusted EBITDA. Adjusted gross profit represents gross profit excluding the fair value charges of acquired inventory, depreciation step-up of acquired fixed assets and the impact of restructuring and other charges. Adjusted gross profit margin is subject to the same adjustments as adjusted gross profit. Organic sales growth calculates sales growth period over period, after excluding the impact of acquisitions, divestitures and foreign exchange rate fluctuations. Free cash flow represents cash flow from operating activities less purchases of property, plant and equipment net proceeds from sale of certain properties. Free cash flow conversion represents free cash flow divided by adjusted net income. These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this presentation. Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.

2025 Guidance




Guidance on certain financial information and operating results of Enovis for the fiscal year ended December 31, 2025 included in this presentation and identified with the caption "2025g" reflect our latest guidance as of January 12, 2026. Enovis' financial closing procedures for the fourth quarter and fiscal year ended December 31, 2025 are not yet complete. Enovis expects that its actual results to be reported in its Annual Report on Form 10-K for the year ended December 31, 2025 will not differ materially from such guidance, however, these results are subject to change following the completion of year-end accounting procedures and adjustments, including the execution of the Enovis' internal control over financial reporting, the completion of the preparation and audit of the Enovis' financial statements and the subsequent occurrence or identification of events prior to the formal issuance of the audited financial statements for fiscal year 2025.

ENOVIS at a Glance

Updated Guidance For 2025

Sales	Y/Y Growth	aEBITDA
~\$2.24-2.25B	~6% Organic	\$400-405M

Sales Mix by Geography & Segment¹



Two Attractive Ortho Business Segments

Fast growing reconstructive (Recon) platform

- Above market growth engine with attractive portfolio
- ~50% of business in fast growing extremities (shoulder / foot & ankle)
- Globalized business to ~50% international through acquisitions of Mathys and Lima

A Global leader in prevention & recovery (P&R)

- Global leader in sports medicine bracing
- Technology leader in recovery sciences with broad offering in advanced rehabilitation modalities
- Reshaping care path with MotionMD® and MotionIQ® digital solutions
- Robust cash generator

Strong Portfolio, Diversified End-Markets, Attractive Growth Drivers

The Fundamentals of Our Strategy

Aggressively Grow Recon

Gain market share in Recon through advantaged products, continuous innovation & global expansion

Shape P&R

Shape P&R to higher growth and gross margin while maintaining strong FCF profile

Commercial Execution & Innovation

Embedding and expanding disciplined commercial practices and accelerating our product development pipeline

Operating Excellence

Drive continuous improvement & productivity leveraging our EGX business system

Financial Discipline


Focused capital allocation to improve cashflow and reduce leverage

Consistent Financial Execution Since Spin in 2022

Revenues

Adjusted Gross Margins

Adjusted EBITDA Margins



Continuing to Drive Balanced Growth and Operating Leverage

Transformation Via +20 Acquisitions

Key Themes:



Globalize Recon



Build differentiated F&A



Advance Enabling Technology



Shape P&R to Higher Growth

LiteCure Laser

MedShape

Trilliant

Mathys

2 technology acquisitions-

NovaStep

Lima Orthopedics

Dr. Comfort (Divestiture)




Accelerated Revenue Growth and Margin Profile since 2019

Shaping Our Company Towards Higher Growth

Percent Mix of Total Enovis Sales¹

- High Growth Categories
- Moderate Growth Categories
- Low Growth Categories



High Growth Categories (HSD/LDD CAGR):

- Shoulder
- Foot & Ankle
- Knee
- Recovery Sciences / New modalities / Bone Growth Stimulation

Moderate Growth Categories (MSD/HSD CAGR):

- Hip
- US Bracing / Healthcare Solutions
- OUS P&R

Low Growth Categories (LSD CAGR):

- US Bracing / Wholesale & Consumer
- Recovery Sciences / Traditional Rehab
- Dr. Comfort (divested in Q4/25)²

Significantly Reshaped the Company Over the Last Three Years

Intentional Global Diversification – Fuels Growth & Margin

International as percentage of Enovis sales:

2019 27%

2025* >42%

Shareholder Value Driven By:

- Focused M&A to build direct & indirect channels
- Expansion via entry into select, profitable markets
- Portfolio cross-selling is a durable, multi-year opportunity
- In-region manufacturing & supply chain optimization to drive global efficiency



Established Global Scale Across Both P&R and Recon

We Are At An Inflection Point In Our Journey

What we have done over the last 5+ years has created a strong foundation...

- Developed a standalone business following a separation from ESAB
- Completed over 20 acquisitions across Recon, P&R, and internationally
- Invested in differentiated medical and enabling technologies across the continuum of care

We've strengthened our foundation and built a talented, committed team that's delivered through rapid growth and change

Looking forward, we want to be a more integrated MedTech company that can drive accelerated performance with...

- Building a One Enovis mindset working collaboratively across the company
- Driving Clarity of purpose with a refined operating model with well-defined roles and responsibilities
- Embedding the DNA of continuous improvement to drive enterprise-wide efficiency and execution

We'll become a leading MedTech company that delivers exceptional impact for patients, employees, and shareholders

Our Vision is to be the Leading Mobility Health MedTech Company

The key to longevity is We are an end-to-end mobility health company



Brain health



Mobility health



Gut health



Prevention



Diagnosis and planning



Surgery



Recovery



Full mobility



STRATEGIC ADVANTAGES


- Brand & contracting leverage with hospitals, surgeons, clinicians, patients
- Digital workflow solutions for clinics
- Connected medicine solutions for patient journey
- Key partner to ambulatory surgery centers (ASC)

Leveraging Broad and Deep Market Access and Technology for Strategic Advantage

\$1.1B Reconstructive Innovator with Attractive Portfolio and Mix

Recon Sales & Market Position¹

\$23B market expected to grow ~4% per year



Market Leadership

- Differentiated products and robust innovation engine & capabilities
- Still very early stages of realizing **global cross-selling benefits** after integrating M&A across the portfolio
- Unparalleled **KOL leadership team & Best-in-Class medical education** across segments
- Proven **Commercial Excellence** track record of above market growth

Industry Leadership

#3

Globally in Shoulder

~2x

WW Hip/Knee growth vs. mkt since '22

#1

Dynamic Fusion Solutions

Technology and Brand Leadership



AltiVate® & SMR



EMPOWR®



Arvis



DynaNail®



Ceramics



3D Printing

Leading in Shoulder, Winning across Recon with Measurably Better Patient Outcomes

enovis.

© 2026 Enovis Corporation

¹ Trailing 12 months represents the historical financial statements of Enovis Corporation. Inclusive of the 9-months YTD through 10/3/25 plus 3 months ended 12/31/2024

Where and How we Continue to Win in Recon

Powerful Differentiated Technologies

- Leading kinematic designs for knee and shoulder implants
- Next Generation Minimally Invasive Solutions
- Ceramys Ceramics
- Dynamic Compression Technology
- Trabecular Titanium, P² Porous Coating
- Proprietary Augmented Reality

Prioritize commercial efforts around key differentiated technologies, and investment in attractive high-growth sub-segments

Commercial Excellence

- World class KOLs and Medical Education programs
- Vibrant “Go-To” destination for top commercial talent
- Proven, EGX driven playbook designed for repeatable, predictive GROWTH
- Leading in the ASC setting
- Meaningful cross-selling across combined Enovis, Mathys, and Lima portfolios

A focused, customer-centric mindset focused on pairing premier medical education programs with robust customer segmentation and targeting across the sales cycle

Leading Innovation Cadence

- Improved NPI processes to streamline development timelines and prioritize the most actionable and innovative commercial opportunities
- Over 30 new product launches planned over next 3 years including key platform launches within each anatomy
- Workflow solutions drive meaningful value and utility across all surgical settings
- Complete foundation of enabling technologies within planning and navigation


Optimized R&D structure to drive productivity and improve efficiency and outcomes across the development cycle

Building a Powerful Complimentary Portfolio Around Proven Growth Playbook

Market Leader in Prevention & Recovery with Differentiated Brands

P&R Sales & Market Position¹

\$5B market expected to grow ~2% per year



Market Leadership

- **Industry-defining** products across Orthopedics
- Sustainable demographic and conservative care demand drivers
- **MotionMD®** workflow software solution **drives workflow productivity** in US Clinics
- **Leader in therapy modalities strengthened by LiteCure™**
- **Strong international position:** 33% ex-US Sales

Industry Leadership

#1

Globally in Bracing

#1

Globally in Rehab

#2

In Bone Stimulation

Technology and Brand Leadership



DonJoy®



Aircast®



EXOS®



SPINALOGIC®



LiteCure®

Attractive Leading Global Positions in Bracing and Recovery Sciences

enovis.

© 2026 Enovis Corporation

¹ Trailing 12 months represents the historical financial statements of Enovis Corporation. Inclusive of the 9-months YTD through 10/3/25 plus 3 months ended 12/31/2024.

² Other represents Dr. Comfort which was divested as of 10/03/25

Shaping P&R - Driving Core Growth & Accelerating Key Strategies

Continue Shaping the Portfolio

- >50% of products/solutions now growing at MSD+
- More frequent NPI focused on growth segments
- Capture share entitlement in Spine, Upper Extremity, and Osteoarthritis Bracing
- Drive High Energy Modalities to standard of care
- Fuel success in attractive channels globally

Prioritize growth in RCM channel, and investment in attractive sub-segments (e.g., Regen, laser, spine)

Drive Operational Excellence & Cash Flow

- Continue efficient cash generation (+100% FCF conversion)
- Improve Gross Margins (e.g. lower cost manufacturing, positive mix, make vs. buy)
- Deliver profit expansion and robust customer experience by leveraging EGX business system

Optimize pricing, supply chain, and net working capital improvement through ongoing initiatives

Focus on Healthcare & Digital Solutions Growth

- Leverage leading MotionMD® solution to convert new clinics and gain share
- Drive deeper penetration and efficiency in served clinics (~45% of US orthopedic clinics currently)
- Continue expanding patient engagement and clinic workflow solutions

Continue to advance solutions with a focus on ASCs leveraging Healthcare Solutions capabilities

Shaping Toward MSD growth with Healthy Cash Flow and Consistent Profit Expansion

We have had a robust cadence of major product launches

2023-2025

Knee



EMPOWR Revision



Zuk



Revision Cones

Hip



Nebula



OrthoDrive Impactor



Optimys

Shoulder



ARG



Prima



Cross System Compatibility

Foot & Ankle



DynaNail



Arsenal



MIS

Bracing & Supports



Knee OA



Spine



Cold Therapy

Recovery Sciences



Manafuse



Laser



Electrotherapy

2026 Key Highlights



Launch **Arvis 2.0** with a multi year cadence of new applications across the global recon portfolio. Provides a broad foundation with for planning & navigation



Launch **OPTIMYS** in the US in late 2026, is the first step to bringing the stem with the best in class 10yr revision rates to the US market




Invest in medical education, and awareness to leverage reimbursement tailwinds from **No-Pain Act** and **OA knee bracing**. Product range expansions for OA, Spine, and Cold Therapy.

Durable Opportunity to Capture Value From Recent Launches

Unlocking Cash Flow Generation

Free Cash Flow Conversion Bridge

FCF/Adjusted Net Income



Drivers of Improvement


- **Integration costs:** Reduction of expenses as acquisition pace slows
- **Working Capital:** Scale and productivity opportunities in inventory
- **CAPEX:** Cost and Operational efficiency
- **Interest:** Debt paydown from generated cash

Clear Path to Improving Free Cash Flow Conversion

Understanding Capex for Growth


2025 CAPEX by Category

Percent of total, %



CAPEX as a percentage of sales

Percent of total Enovis, %



Investing in Key Long-Term Growth and Operating Initiatives

We Are Shaping Our Future:

Enovis is committed to innovation, commercial excellence, consistent operating leverage and delivering shareholder value over our long-range plan

M/HSD Organic growth

HSD/DD Recon + LSD/MSD P&R

+50 bps annual margin expansion

+70% FCF conversion

Scaling over time

Looking to 2026

MSD Organic growth

+50 bps aEBITDA expansion

>25% FCF conversion

Appendix



enovis[™]
Creating Better Together[™]

2025 Guidance Update

Reported Revenue

\$2.24-2.25B

(from \$2.24-2.27B)

expected to grow:

**High single-digit Recon
Low single-digit P&R**

Adjusted EBITDA

\$400-405M

(from \$395-405M)

Adjusted EPS

\$3.25-\$3.35

(from \$3.10-\$3.25)

Guidance Within Range of Last Update, Reiterate Positive Free Cash Flow for FY

Gross Margin Bridge

Enovis Corporation
 Reconciliation of Gross Margin (GAAP) to Adjusted Gross Margin (non-GAAP)
 Dollars in millions
 (Unaudited)

	Year Ended			
	December 31, 2024	December 31, 2023	December 31, 2022	December 31, 2021
Net Sales	\$ 2,107.6	\$ 1,707.2	\$ 1,563.1	\$ 1,426.2
Gross profit	\$ 1,108.8	\$ 990.8	\$ 869.4	\$ 777.7
Gross Margin (GAAP)	56.0 %	58.0 %	55.6 %	54.5 %
Gross profit (GAAP)	\$ 1,180.8	\$ 990.8	\$ 869.4	\$ 777.7
Inventory step-up	51.7	0.1	12.8	10.8
Restructuring and other charges	17.9	2.6	1.7	5.2
Adjusted gross profit (Non-GAAP)	\$ 1,250.4	\$ 993.5	\$ 883.9	\$ 793.7
Adjusted gross profit margin (Non-GAAP)	59.3 %	58.2 %	56.5 %	55.7 %

Adjusted EBITDA Reconciliation

Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions
(Unaudited)

	Year Ended			
	December 31, 2024	December 31, 2023	December 31, 2022	December 31, 2021
Net loss from continuing operations (GAAP)	\$ (827.4)	\$ (53.8)	\$ (38.2)	\$ (102.3)
Income tax benefit	4.5	(13.3)	36.1	(19.5)
Other (income) expense, net	(9.9)	(25.7)	(2.1)	-
Unrealized (gain) loss on investment in ESAB Corp	-	-	(102.7)	-
Gain on cost basis investment	-	-	(8.8)	-
Debt extinguishment charges	-	7.3	20.4	29.9
Interest expense, net	57.1	19.7	24.1	29.1
Operating loss (GAAP)	(775.7)	(65.7)	(71.2)	(62.8)
Adjusted to add:				
Restructuring and other charges ⁽¹⁾	45.2	20.0	19.0	13.9
MDR and other costs ⁽²⁾	19.5	27.4	16.7	7.9
Strategic transaction costs ⁽³⁾	78.3	38.3	61.0	23.4
Stock-based compensation	29.7	32.1	31.5	25.7
Depreciation and other amortization	117.3	83.6	76.7	70.1
Amortization of acquired intangibles	165.5	133.5	126.3	116.9
Goodwill impairment charge	645.0	-	-	-
Insurance settlement loss	-	-	(36.7)	-
Inventory step-up	51.7	0.1	12.8	10.8
Adjusted EBITDA (non-GAAP)	\$ 376.5	\$ 269.2	\$ 236.1	\$ 205.9
Adjusted EBITDA margin (non-GAAP)	17.9 %	15.8 %	15.1 %	14.4 %

⁽¹⁾ Restructuring and other charges includes \$17.9 million, \$2.6 million, \$1.7 million, and \$5.2 million of expense classified as Cost of sales on our Consolidated Statements of Operations for the year ended December 31, 2024, December 31, 2023, December 31, 2022, and December 31, 2021, respectively.

⁽²⁾ Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

⁽³⁾ Strategic transaction costs includes integration costs related to recent acquisitions and ESAB Separation-related costs.



Free Cash Flow Conversion

Enovis Corporation
Reconciliation of Free Cash Flow Conversion
Dollars in millions
(Unaudited)

	Year Ended	
	December 31, 2024	
Net cash provided by (used in) operating activities	\$	113.5
Purchases of property, plant and equipment and intangibles		(180.7)
Free Cash Flow	\$	(67.2)
Adjusted Net Income		158.1
Free Cash Flow Conversion ⁽¹⁾		-43%

⁽¹⁾ Free Cash Flow conversion = Free Cash Flow/Adjusted Net Income



enovis™

Creating Better Together™